A double-blind, placebo-controlled, multicenter study of 90 patients found that intramuscular ALC (500 mg twice daily for 14 days followed by oral ALC 1,000 mg twice daily for 42 days) produced significantly greater reduction in pain compared with placebo in the efficacy-evaluable population (P=0.022).[4] An open cohort study of 21 HIV-positive patients with established ATN treated with oral ALC 1,500 mg twice daily for up to 33 months demonstrated remarkable nerve regeneration: mean immunostaining area for small sensory fibers increased 100% in epidermis and 133% in dermis after 6 months, with neuropathic grade improving in 76% of patients.[5] However, a subsequent open-label study found that while ALC therapy coincided with improvements in subjective measures of pain, changes were not observed in objective measures of intra-epidermal nerve fiber density or mitochondrial DNA levels.[6] Context with Other Treatments: Second-line or adjunctive therapy for ATN
Changes in the study design, such as the species employed (either rat or mouse), the method and length of exposure, the age at which exposure occurred, and the dose, also lead to differences in the results
Its also believed to contribute to better sleep quality and a sense of overall well-being
Mixing ratio option 2: 3 mL bacteriostatic water (3.33 mg/mL) This is the most commonly recommended ratio for 10 mg vials
